Related Experiment Video
Updated: Mar 10, 2026

Characterization of a Pathogenic Escherichia coli Strain Derived from Oreochromis spp. Farms Using Whole-Genome Sequencing
Published on: December 23, 2022
Escherichia coli ST131 Drives Carbapenem Use for E. coli Bloodstream Infections
Natalie A Mackow1, Wanying Shao2, Lizhao Ge2
1Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Ceftriaxone-resistant Escherichia coli infections are increasingly driven by the ST131 strain, especially the C2/H30Rx subclade. This finding highlights the need for updated treatment strategies for these resistant infections.
Area of Science:
- Infectious Diseases
- Microbiology
- Antimicrobial Resistance
Background:
- Ceftriaxone-resistant Escherichia coli (E. coli) infections are a growing public health concern.
- The emergence of E. coli sequence type 131 (ST131), particularly its C2/H30Rx subclade producing extended-spectrum β-lactamases (ESBL), is a key factor in this rise.
Purpose of the Study:
- To compare bloodstream infections (BSI) caused by E. coli ST131 versus non-ST131 strains.
- To specifically investigate the characteristics and outcomes of infections involving the E. coli ST131 C2/H30Rx subclade.
Main Methods:
- A prospective cohort study was conducted across 14 US sites.
- Monomicrobial E. coli BSI cases (ceftriaxone-resistant and susceptible) were enrolled in a 1:1 ratio.
- Desirability of outcome ranking (DOOR) was assessed at 30 days post-infection.
Main Results:
- E. coli ST131 accounted for 43% of E. coli BSI cases, with 23% belonging to the C2/H30Rx subclade.
- Ceftriaxone resistance was significantly higher in ST131 (79%) and C2/H30Rx (86%) compared to non-ST131 strains (27%).
- Patients with ST131 BSI were older, more likely from long-term care facilities, and received more carbapenem therapy.
Conclusions:
- The E. coli ST131 strain, especially the C2/H30Rx subclade, is a primary driver of ceftriaxone-resistant E. coli bloodstream infections in the US.
- These findings underscore the importance of ST131 in necessitating increased carbapenem use for treating resistant E. coli infections.
More Related Videos
Related Concept Videos
Stringent Response in E. coli
Acute Pyelonephritis II: Diagnostic Studies and Management
Endocarditis I: Introduction
Urinary Tract Infection I: Introduction
Special Staining Techniques
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

